Antibiotic resistance and rare diseases were among the topics explored by a panel of scientists and pharmaceutical industry representatives in Marburg, Germany.
By Dr. Lutz Bonacker
May 8, 2017
Philipps University of Marburg, Germany, where members of the scientific and pharmaceutical communities examined a range of timely topics.
Earlier this year I joined distinguished members of the scientific and pharmaceutical communities for an academic panel hosted by Philipps University of Marburg, Germany, where CSL Behring operates a manufacturing and R&D facility for recombinant and plasma-derived coagulation factors, C-1 inhibitor and critical care products.
April 2, 2015
By Jeannie Joughin, Ph.D.
The patient experience can be significantly enhanced by more convenient delivery systems.
Forming partnerships with other organizations when it makes sense to do so is an important part of CSL Behring’s business strategy. One organization alone cannot address the world’s most pressing issues, such as treating rare or serious diseases. Together, partnerships can accomplish far more than individual standalones. Collaborations can unite strengths and unleash unprecedented capabilities.